Moderna’s Dr. Stephen Hoge on AI and the Future of Healthcare

Private equity investment remains robust despite elevated interest rates, with significant activity in the energy and defense sectors. The U.S. economy demonstrates resilience through energy independence and strong corporate earnings, though high government debt and geopolitical instability present ongoing challenges. Artificial intelligence is fundamentally transforming drug discovery, enabling rapid development of personalized mRNA therapies. Moderna’s recent melanoma trials highlight this shift, as researchers now design vaccines tailored to an individual’s unique cancer mutations, achieving significant improvements over traditional immunotherapies. While AI accelerates the design phase, physical constraints in clinical trial enrollment and manufacturing remain critical pacing factors for bringing these treatments to market. This evolution in biotechnology, supported by substantial capital investment, signals a new era for personalized medicine, moving beyond one-size-fits-all treatments toward highly targeted, patient-specific interventions.